SCHEMBL8238583

SCHEMBL8238583

CC(C)(C)OC(=O)N1CCN(C(=O)c2ncn([C@H]3CCNC3)c2-c2ccccc2)[C@H](Cc2ccccc2)C1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABHD6 Q9BV23 1/20 0.46
DAGLA Q9Y4D2 1/20 0.46
PARP1 P09874 1/20 0.42
DPP4 P27487 1/20 0.41
NR1H2 P55055 2/20 0.41
NR1H3 Q13133 2/20 0.41
HDAC1 Q13547 1/20 0.39
EGFR P00533 1/20 0.38
SRC P12931 1/20 0.38
USP30 Q70CQ3 1/20 0.38
HPGDS O60760 2/20 0.38
CA1 P00915 6/20 0.37
CA2 P00918 6/20 0.37
CA4 P22748 6/20 0.37
CA9 Q16790 6/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8238449 1.00 ABHD6 (0.46) ABHD6DAGLAPARP1DPP4NR1H2
SCHEMBL8238579 1.00 ABHD6 (0.46) ABHD6DAGLAPARP1DPP4NR1H2
SCHEMBL8230034 0.96 ABHD6 (0.44) ABHD6DAGLAPARP1DPP4NR1H2
SCHEMBL13705167 0.90 ABHD6 (0.47) ABHD6DAGLAPARP1DPP4NR1H2
SCHEMBL3495613 0.90 CA1 (0.40) CA1CA2CA4CA9
SCHEMBL3494442 0.90 CA1 (0.40) CA1CA2CA4CA9
SCHEMBL3493485 0.90 CA1 (0.40) CA1CA2CA4CA9
SCHEMBL8238426 0.89 ABHD6 (0.47) ABHD6DAGLAPARP1DPP4NR1H2
SCHEMBL8235939 0.88 ABHD6 (0.46) ABHD6DAGLAPARP1DPP4NR1H2
SCHEMBL8237252 0.88 ABHD6 (0.46) ABHD6DAGLAPARP1DPP4NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
WO-2007094513-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 ABHD6 2780/4885DAGLA 4388/4885PARP1 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.